A worldwide clinical study is underway for an innovative investigational vaccine that may help people with Chronic Obstructive Pulmonary Disease (COPD) reduce episodes of exacerbations, commonly known as flare-ups. Palmtree Clinical Research (PCR), a multi-specialty clinical research firm based in Palm Springs, was selected as a study site, and volunteers are currently being accepted with enrollment expected to close by the end of the year.

The study is open to adults age 40 to 80 who have been diagnosed with moderate-to-severe COPD. About half the people with COPD experience periodic flare-ups that warrant medical intervention such as emergency or urgent care visits and/or a change in their COPD medication regimen. “Higher exacerbation rates have been linked to a faster decline in lung function and could have a negative effect on a person’s quality of life,” explains Ziad Tannous, MD, a pulmonologist and the principal investigator of the trial.

According to research scientists, non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) appear to be the main organisms associated with flare-ups. Thus, these are the two bacteria this investigational vaccine is designed to target. In earlier stages of development, this investigational vaccine was successfully administered to healthy adults.

Participants will receive the NTHi/Mcat vaccine or a placebo at no cost. They also receive study-related medical care by a team of qualified medical professionals throughout the course of the study and receive compensation for their time and transportation to attend each study visit. Eligible candidates will need to sign an informed consent form in order to enroll.

“People who volunteer for this clinical study may play a crucial role in paving the way for future treatments of COPD for themselves and others with this condition,” adds Carlos Martinez, MD, chief medical officer at Palmtree Clinical Research.

Pulmonology is just one of the subspecialties in which PCR offers studies for potential leading-edge treatment. In addition to the COPD vaccine study, there are 11 other clinical trials in which Southern California residents may participate if qualified, including psoriasis, idiopathic pulmonary fibrosis, HIV, eczema, diabetes, gastrointestinal conditions and women’s health.

Prior studies that were conducted at Palmtree Clinical Research which have now received FDA approval include Eucrisa, a non-steroidal topical cream for eczema; Vancomycin, a medication to treat C. difficile infections; Trogarzo, approved earlier this year for HIV treatment experienced patients; and Tivicay which is now widely prescribed to treat people with HIV.

To find out more about the COPD vaccine study or any other current trials, contact Palmtree Clinical Research at (760) 777.7799 or visit www.palmtreeclinical.com.